Skip to main content
Professional Technical IVT

Lenalidomide

Pronunciation: len-ah-LID-oh-myde

An immunomodulatory drug (IMiD) used in multiple myeloma and certain lymphomas with anti-angiogenic and immunomodulatory properties.

Full Definition

Lenalidomide is an oral immunomodulatory agent derived from thalidomide with enhanced efficacy and reduced toxicity profile. It works through multiple mechanisms including immune system modulation, anti-angiogenesis, and direct cytotoxic effects on malignant plasma cells. Lenalidomide is a cornerstone therapy for multiple myeloma, used in both newly diagnosed and relapsed/refractory settings. The drug requires strict adherence to pregnancy prevention programs due to teratogenic risk. Common side effects include myelosuppression, thromboembolism risk, and secondary malignancies with prolonged use.

Usage

Usage note: Document REMS program compliance when prescribing; specify pregnancy prevention measures in female patients.

In Context

  • "The patient achieved a very good partial response to lenalidomide maintenance therapy." — Response assessment documentation
  • "Lenalidomide was dose-reduced to 15 mg daily due to grade 3 neutropenia." — Dose modification note

Also known as

Revlimid IMiD CC-5013

Don't confuse with

thalidomide pomalidomide

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON